All News
#ACR21 TM26. Familial chilblains lupus seen in genetic mutation in Three Prime Repair Exonuclease 1 (TREX1). Suspected due to onset in infancy.
@Rheumnow https://t.co/ZryOpeoJT8 https://t.co/LqZqoGDAL2
Links:
Eric Dein ericdeinmd ( View Tweet)
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof)
It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?
https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
Links:
Dr. John Cush RheumNow ( View Tweet)
GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O
Richard Conway RichardPAConway ( View Tweet)
#ACR21 #Abstr1909 📢We need to stress the importance of hydroxychloroquine adherence to our patients. Adherence (>90% of the time) reduced premature CVD mortality by 52% in #rheumatoidarthritis and #lupus. The study didn’t adjust for smoking @RheumNow https://t.co/D9pGqwWhje https://t.co/R6r3cSexUB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
HCQ adherence (>90%) associated with 52% reduced cardiovascular mortality in RA and SLE. Seen for MI, stroke, not VTE. Abstr#1909 #ACR21 @RheumNow https://t.co/5UncmqZVNp
Richard Conway RichardPAConway ( View Tweet)
Claims data looked at 21,114 #RA & #SLE pts - 4.3% had CV Death. The risk of CVD was worse w/ HCQ nonadherence (HR 1.08; 0.91-1.31) and better w/ HCQ adherence (HR 0.51;0.42-.66) HCQ nonadherence shows higher CV mortality #ACR21 Abst# 1909 https://t.co/di1mBliMN6
Dr. John Cush RheumNow ( View Tweet)
#ACR21 TM18
⭐️Spontaneous coronary artery dissection (SCAD) of LAD
▶️ +Sicca, Photosensitivity, malar erythema, alopecia, oral ulcers, arthralgias
▶️ ANA negative, dsDNA HIGH
Rare case of ANA negative SLE with odd presentation!
https://t.co/jfmVtZ4iOV @RheumNow https://t.co/pMHcColeUn
Links:
Eric Dein ericdeinmd ( View Tweet)
60% don’t use pneumocystis prophylaxis #PJP in #lupus #SLE @RheumNow #ACR21 https://t.co/AVf97xJhtL
Janet Pope Janetbirdope ( View Tweet)
SLE Panel: Learning about Lupus
Drs. Kathryn Dao, Janet Pope, Yuz Yusof, Bella Mehta and Pedro Castillo discuss lupus-related data presented at #ACR21.
@KDAO2011 @Janetbirdope @Yuz6Yusof @bella_mehta @_Castillo_Pedro
https://t.co/RPl6ZqWS05 https://t.co/mdTyocBbr2
Links:
Dr. John Cush RheumNow ( View Tweet)
🆕 Main findings of #Lupus trials presented at #ACR21 ⬇️ https://t.co/HENxcyLuf5
Laurent ARNAUD Lupusreference ( View Tweet)
Dr. Melissa Munroe - Lupus Classification Risk Immune Index
🔹Pre-/post-classification serum
🔹Avg time➡️classification 4.7y
🔹9 immune mediators altered in pre-clinical dz
🔹Pos score = ⬆️likelihood➡️SLE; Neg = ⬇️
https://t.co/UFEkGieXum
1/2
#ACR21 Abst#1423 @RheumNow #ACRBest
Pedro Castillo _Castillo_Pedro ( View Tweet)
ANA negative SLE! Lunch w/Dr. John P Atkinson. When I was in training @WUSTLrheum he bet that if you come across a case of ANA neg- SLE that is convincing, he will buy lunch. Great case of SLE following spont coronary artery dissection. #ThievesMarket #ACR21 Abst#TM18 @rheumnow https://t.co/TRyQaJ4kbR
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Despotovic shares general principles about ICU admissions in patients w/ #rheumatic disease.
🔺#SLE, RA, systemic #vasculitis, SSc, IIMs
🔺serologic testing useful but interpret w/n clinical context
@RheumNow #ACR21 https://t.co/jb3Mt31dZz
sheila RHEUMarampa ( View Tweet)
#ACR21 Thieves: SLE and SSc with worsening cytopenia and hematuria despite treatment:
Maria Powell - presents overlap case with PNH, responded to eculizumab
@Rheumnow https://t.co/CGvHEMA3lI
Eric Dein ericdeinmd ( View Tweet)
⬆HCQ blood levels significantly associated w/ ⬇ in mean SLEDAI, UPCR, SBP & platelet cts
🔷Assoc'n strongest in HCQ conc'n in range 0-1000ng/mL
A possible HCQ blood level target to ⬇ 👁toxicity?🤔
@RheumNow #ACR21 abs1753 https://t.co/3jkDDakIcb
sheila RHEUMarampa ( View Tweet)
Interesting study on Pioglitazone significantly improving vascular stiffness and cardiometabolic parameters vs. PBO in #lupus by @sarfarazhasni et al.
Pioglitazone: potential tx option to reduce CV risk in SLE?🧐
@RheumNow #ACR21 abs1748 https://t.co/ow3zA2hhnx
sheila RHEUMarampa ( View Tweet)
In this study:
💊No correlation bet QTc interval & whole blood HCQ level regardless of dose, CKD or abnormal TTEs in #lupus pts
💊+correlation bet QTci & HCQ levels in pts w/ QTc prolonging drugs but not >456ms
Reassuring, dispels concern on HCQ use
@RheumNow #ACR21 abs1743 https://t.co/kpASRAXJB1
sheila RHEUMarampa ( View Tweet)
#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts:
❌No ⬆️ in disease activity scores post-vaccination
❌No serious adverse event
▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls
⭐️RTX and MMF ⬇️ responses
@Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 #Abstr1491 What’s new in skin #lupus aetiology? Paired skin & blood using scRNA-seq:
💠Nonlesional skin in CLE/SLE is IFN-I-riched
💠Lupus-enriched CD16+ DCs undergo robust IFN education in the skin & gained pro-inflammatory phenotypes @RheumNow https://t.co/70zrC4T7SB https://t.co/75HjvGmNTa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In this study by Prof MAringer et al, majority of #lupus pts enrolled in TULIP 1/2 met the the EULAR/ACR 2019 #SLE criteria
🦋Of few pts not meeting new criteria, most were ANA- w/detectable anti-dsDNA/Smith Ab
Better outcomes for criteria+ in TULIP1/2?
@RheumNow #ACR21 abs1733 https://t.co/XpfMZQLGUv
sheila RHEUMarampa ( View Tweet)
